After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Rhythm Pharmaceuticals Inc is $7.26B. A total of 0.6 million shares were traded on the day, compared to an average of 638.15K shares.
In the most recent transaction, Cramer Pamela J. sold 3,350 shares of RYTM for 105.00 per share on Nov 20 ’25. After the transaction, the Chief Human Resources Officer now owns 20,814 company shares. In a previous transaction on Nov 20 ’25, PAMELA CRAMER bought 3,350 shares at 103.15 per share.
Among the insiders who sold shares, Cramer Pamela J. disposed of 19,351 shares on Nov 07 ’25 at a per-share price of $98.82. This resulted in the Chief Human Resources Officer holding 20,814 shares of RYTM after the transaction. In another insider transaction, Cramer Pamela J. sold 3,515 shares at $100.00 per share on Nov 10 ’25. Company shares held by the Chief Human Resources Officer now total 20,814.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, RYTM has a high of $116.00 and a low of $45.90.
As of this writing, RYTM has an earnings estimate of -$0.75 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.27 per share and a lower estimate of -$0.96. The company reported an EPS of -$0.72 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RYTM’s latest balance sheet shows that the firm has $294.86M in Cash & Short Term Investments as of fiscal 2021. There were $2.55M in debt and $43.43M in liabilities at the time. Its Book Value Per Share was $2.23, while its Total Shareholder’s Equity was $284.15M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RYTM is Buy with a score of 4.67.
